Edition:
United States

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

48.98USD
10:49am EDT
Change (% chg)

$-1.05 (-2.10%)
Prev Close
$50.03
Open
$49.87
Day's High
$50.46
Day's Low
$48.96
Volume
60,101
Avg. Vol
457,842
52-wk High
$55.05
52-wk Low
$30.76

MDCO.OQ

Chart for MDCO.OQ

About

The Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute... (more)

Overall

Beta: 0.76
Market Cap(Mil.): $3,571.16
Shares Outstanding(Mil.): 71.38
Dividend: --
Yield (%): --

Financials

  MDCO.OQ Industry Sector
P/E (TTM): -- 29.56 30.32
EPS (TTM): -1.79 -- --
ROI: -8.77 13.57 13.10
ROE: -17.01 14.48 14.24

Medicines Co drug shows long-term cholesterol lowering in study

WASHINGTON A long-acting new type of drug being developed by Medicines Co cut levels of "bad" LDL cholesterol in half in high-risk heart patients with no serious safety issues, according to data from a Phase II trial presented on Friday.

Mar 17 2017

Medicines Co drug shows long-term cholesterol lowering in study

WASHINGTON, March 17 A long-acting new type of drug being developed by Medicines Co cut levels of "bad" LDL cholesterol in half in high-risk heart patients with no serious safety issues, according to data from a Phase II trial presented on Friday.

Mar 17 2017

BRIEF-Medicines Co reports Q4 loss per share $1.77 from continuing operations

* The Medicines Company reports fourth-quarter and full-year 2016 financial results

Feb 28 2017

BRIEF-Medicines Co says FDA accepts NDA filing for intravenous antibiotic carbavance

* The Medicines Company announces FDA filing acceptance of new drug application for intravenous antibiotic carbavance(meropenem-vaborbactam)

Feb 21 2017

BRIEF-Mylan signs sub-license agreement with the Medicines Patent Pool to produce and market DAKLINZA tablets to 112 countries

* Mylan signs sub-license agreement with the Medicines Patent Pool to increase access to Hepatitis C treatment in developing countries

Nov 28 2016

BRIEF-The Medicines Company, Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran

* The Medicines Company and Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of Inclisiran (formerly PCSK9si)

Nov 15 2016

Long-lasting cholesterol lowering seen with Medicines Co drug: study

NEW ORLEANS A new type of heart drug developed by Medicines Co significantly lowered "bad" LDL cholesterol in high-risk patients with no major safety issues, according to data from a midstage trial that helped the company identify the dose it will move into advanced testing.

Nov 15 2016

Long-lasting cholesterol lowering seen with Medicines Co drug -study

NEW ORLEANS, Nov 15 A new type of heart drug developed by Medicines Co significantly lowered "bad" LDL cholesterol in high-risk patients with no major safety issues, according to data from a midstage trial that helped the company identify the dose it will move into advanced testing.

Nov 15 2016

BRIEF-Alnylam Pharmaceuticals, Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran

* Results from study showed doses 300 mg significantly reduced pcsk9 and ldl cholesterol for at least 6 months

Nov 13 2016

BRIEF-Medicines Co says discontinues development of MDCO-216

* Medicines Co says discontinues development of MDCO-216, its investigational cholesterol efflux promoter

Nov 07 2016

More From Around the Web

Earnings vs. Estimates